Leukemia Clinical Trial
Official title:
Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin,
work in different ways to stop cancer cells from dividing so they stop growing or die.
Combining more than one drug may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide
when given together with cytarabine and idarubicin in treating patients with acute myeloid
leukemia.
Status | Completed |
Enrollment | 61 |
Est. completion date | December 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 59 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed de novo or secondary acute myeloid leukemia with = 20% blasts AND at least 1 of the following characteristics*: - Auer rods - Peroxidase or sudan black positive blasts - Chloroacetate esterase-positive or diffusely non-specific esterase-positive blasts - Presence of a myeloid immunophenotype by multiparameter flow cytometry, including expression of one or more myeloid markers (CD13, CD33) on blasts NOTE: *Megakaryocytic leukemia can be diagnosed by the detection of platelet antigens (e.g. factor VIII, glycoprotein Ib or IIb/IIIa) using monoclonal antibodies or the presence of ultrastructural platelet peroxidase - No acute promyelocytic leukemia - No Philadelphia-chromosome positive chronic myeloid leukemia - Prior hematologic disorders, including myelodysplastic syndromes, aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myeloproliferative disorders allowed PATIENT CHARACTERISTICS: Age - 18 to 59 Performance status - Not specified Life expectancy - More than 4 weeks Hematopoietic - Not specified Hepatic - Bilirubin = 2 times normal* - SGOT = 2 times normal* - Alkaline phosphatase = 2 times normal* NOTE: *Unless abnormalities are directly attributable to leukemia Renal - Creatinine = 1.5 times normal* NOTE: *Unless abnormalities are directly attributable to leukemia Cardiovascular - Cardiac ejection fraction = 45%* - Absolute QT interval = 460 msec with potassium > 4.0 mEq/L and magnesium > 1.8 mg/dL - No myocardial infarction within the past 6 months - No uncontrolled symptomatic congestive heart failure - No angina pectoris - No multifocal cardiac arrythmias - No other severe cardiovascular disease NOTE: *Unless abnormalities are directly attributable to leukemia Other - No serious medical or psychiatric illness that would preclude informed consent or limit survival to < 4 weeks - No uncontrolled diabetes mellitus - No other concurrent active malignancy - No known hypersensitivity to E. coli-derived drug preparations - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy for acute leukemia, except hydroxyurea to control white blood cell counts - Prior chemotherapy for an antecedent malignancy or other medical condition allowed Endocrine therapy - Not specified Radiotherapy - Prior radiotherapy for an antecedent malignancy or other medical condition allowed Surgery - Not specified |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Roswell Park Cancer Institute | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
Roswell Park Cancer Institute | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose and/or biologically effective dose or arsenic trioxide | 30 days after completion of study treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |